At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences
Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)
Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed
Presentation on September 30, 2023
Anders brings nearly 30 years of international and diverse experience in oncology-focused drug development and commercialization.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.
Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences
All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported
Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer
Poster discussion session on June 5, 2023 at 1:15 p.m. ET
Oncoinvent shareholders have recently elected new board members and the board now comprises Roy Larsen (Executive Chairman), Øyvind Bruland, Petter Fjellstad, Thora Jonasdottir, Anne Cecilie Alvik and Mona-Elisabeth Revheim.
Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals. Further updates will be provided in an upcoming investor conference call.
First patient has been treated in the RAD-18-002 phase 2A clinical study
All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.
Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.